Product Name :
CNV1014802 hydrochloride
Description:
CNV1014802 hydrochloride is a novel analgesic under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN). It acts as a selective, small-molecule, state-dependent Nav1.7 voltage-gated sodium channel blocker.
CAS:
934240-31-0
Molecular Weight:
350.82
Formula:
C18H20ClFN2O2
Chemical Name:
(2S,5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide hydrochloride
Smiles :
Cl.NC(=O)[C@@H]1CC[C@@H](N1)C1C=CC(=CC=1)OCC1=CC=CC=C1F
InChiKey:
HEPUBAGOKRIZEO-PPPUBMIESA-N
InChi :
InChI=1S/C18H19FN2O2.ClH/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22;/h1-8,16-17,21H,9-11H2,(H2,20,22);1H/t16-,17+;/m1./s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
CNV1014802 hydrochloride is a novel analgesic under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN). It acts as a selective, small-molecule, state-dependent Nav1.7 voltage-gated sodium channel blocker.|Product information|CAS Number: 934240-31-0|Molecular Weight: 350.82|Formula: C18H20ClFN2O2|Synonym:|GSK-1014802|CNV-1014802|Raxatrigine|Raxatrigine hydrochloride|Vixotrigine|GSK1014802|GSK 1014802|CNV1014802|CNV 1014802|Chemical Name: (2S,5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide hydrochloride|Smiles: Cl.NC(=O)[C@@H]1CC[C@@H](N1)C1C=CC(=CC=1)OCC1=CC=CC=C1F|InChiKey: HEPUBAGOKRIZEO-PPPUBMIESA-N|InChi: InChI=1S/C18H19FN2O2.ClH/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22;/h1-8,16-17,21H,9-11H2,(H2,20,22);1H/t16-,17+;/m1./s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO, not in water|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.{{Naloxone} MedChemExpress|{Naloxone} Neuronal Signaling|{Naloxone} Technical Information|{Naloxone} Formula|{Naloxone} custom synthesis|{Naloxone} Autophagy} |Drug Formulation: To be determined.{{Sumatriptan} web|{Sumatriptan} Neuronal Signaling|{Sumatriptan} Purity & Documentation|{Sumatriptan} In Vitro|{Sumatriptan} supplier|{Sumatriptan} Epigenetic Reader Domain} |HS Tariff Code: 382200|How to use|In Vitro:|Like lamotrigine, both GSK2 and GSK3 were able to prevent the deficit in reversal learning produced by PCP, thus confirming their potential in the treatment of cognitive symptoms of schizophrenia.PMID:27017949 However, higher doses than those required for anticonvulsant efficacy of the drugs were needed for activity in the reversal-learning model, suggesting a lower therapeutic window relative to mechanism-dependent central side effects for this indication. CNV1014802 hydrochloride (GSK-1014802) received orphan-drug designation from the US Food and Drug Administration in July 2013.|References:|Deuis JR, Wingerd JS, Winter Z, Durek T, Dekan Z, Sousa SR, Zimmermann K, Hoffmann T, Weidner C, Nassar MA, Alewood PF, Lewis RJ, Vetter I. Analgesic Effects of GpTx-1, PF-04856264 and CNV1014802 in a Mouse Model of NaV1.7-Mediated Pain. Toxins (Basel). 2016 Mar 17;8(3). pii: E78. doi: 10.3390/toxins8030078. PubMed PMID: 26999206; PubMed Central PMCID: PMC4810223.Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA. Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3690-9. doi: 10.1016/j.bmcl.2014.06.038. Epub 2014 Jun 21. Review. PubMed PMID: 25060923.Zakrzewska JM, Palmer J, Ettlin DA, Obermann M, Giblin GM, Morisset V, Tate S, Gunn K. Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia. Trials. 2013 Nov 23;14:402. doi: 10.1186/1745-6215-14-402. PubMed PMID: 24267010; PubMed Central PMCID: PMC4222641.Products are for research use only. Not for human use.|
